Autonomic Nervous System Drugs Practice Questions

Q: Which of the following drugs is not used for the treatment of overactive bladder?

Duloxetine. ***Duloxetine*** - **Duloxetine** is a **serotonin-norepinephrine reuptake inhibitor (SNRI)** primarily used to treat major depressive disorder, generalized anxiety disorder, neuropathic pain, and **stress urinary incontinence (SUI)** [3]. - While it affects neurotransmitters involved in bladder control, its primary indication is SUI through increasing urethral sphincter tone, not directly treating the urgency and frequency associated with **overactive bladder (OAB)** [3]. *Darifenacin* - **Darifenacin** is a **M3 muscarinic receptor antagonist** that selectively targets receptors in the bladder, reducing detrusor muscle contractions [1]. - This action helps to alleviate symptoms of urgency, frequency, and urge incontinence characteristic of **overactive bladder (OAB)** [1]. *Oxybutynin* - **Oxybutynin** is a **non-selective muscarinic receptor antagonist** that relaxes the detrusor muscle of the bladder, decreasing bladder contractility [1], [2]. - It is a long-standing and commonly used medication for managing the symptoms of **overactive bladder (OAB)** and neurogenic bladder [2]. *Flavoxate* - **Flavoxate** is a **direct relaxant of smooth muscle** in the urinary tract, and it has mild anticholinergic, local anesthetic, and analgesic properties. - It is used to relieve symptoms like dysuria, urgency, and nocturia associated with various urinary tract conditions including **overactive bladder (OAB)** and interstitial cystitis.

Q: The drug used in an ameliorative test for myasthenia gravis is

Edrophonium. ***Edrophonium*** - **Edrophonium** is a **short-acting acetylcholinesterase inhibitor** used in the **Tensilon test** for diagnosing myasthenia gravis. - Its rapid onset and brief duration of action (5-10 minutes) allow for quick assessment of symptomatic improvement in patients with the disease. *Physostigmine* - **Physostigmine** is an **acetylcholinesterase inhibitor** that can cross the **blood-brain barrier**, making it useful for treating anticholinergic toxicity. - It has a longer duration of action than edrophonium and is not typically used for the acute diagnostic test of myasthenia gravis. *Tacrine* - **Tacrine** is an **acetylcholinesterase inhibitor** primarily used in the management of **Alzheimer's disease** to improve cognitive function. - It is not used for the diagnosis or short-term ameliorative testing of myasthenia gravis. *Pyridostigmine* - **Pyridostigmine** is an **intermediate-acting acetylcholinesterase inhibitor** used for the chronic symptomatic treatment of myasthenia gravis. - While it improves muscle strength, its longer duration of action (3-6 hours) makes it unsuitable for the rapid diagnostic "Tensilon test."

Q: Which of the following is not a carbamate?

Edrophonium. ***Edrophonium*** - **Edrophonium** is a **short-acting acetylcholinesterase inhibitor** that is not a carbamate. - Its action is very rapid in onset and brief in duration, unlike carbamates which have a longer duration of action due to a more stable bond with acetylcholinesterase. *Physostigmine* - **Physostigmine** is a **tertiary amine carbamate** that can cross the blood-brain barrier. - It works by reversibly inhibiting acetylcholinesterase, leading to increased acetylcholine levels, and has a duration of action of 2-4 hours. *Neostigmine* - **Neostigmine** is a **quaternary ammonium carbamate** that does not cross the blood-brain barrier effectively. - It is used to treat myasthenia gravis and reverse the effects of non-depolarizing neuromuscular blockers, with a duration of action of 2-4 hours. *Pyridostigmine* - **Pyridostigmine** is also a **quaternary ammonium carbamate** and is commonly used for the long-term treatment of myasthenia gravis. - Like neostigmine, it does not cross the blood-brain barrier and has a longer duration of action (3-6 hours) compared to physostigmine.

Q: Sympathomimetic drugs are useful in the therapy of all of the following conditions except:

Hypertension. ***Hypertension*** - Sympathomimetic drugs **mimic the effects of the sympathetic nervous system**, leading to **increased heart rate, contractility, and vasoconstriction**, which would worsen hypertension. - Their primary action is to activate **adrenergic receptors**, thereby elevating blood pressure rather than lowering it. - Sympathomimetics are **contraindicated in hypertensive patients** as they would exacerbate the elevated blood pressure. *Hypotension* - Sympathomimetic drugs are highly effective in treating hypotension, particularly in conditions like **shock**. - They cause **vasoconstriction (alpha-1 agonism)** and/or **increased cardiac output (beta-1 agonism)**, thereby raising blood pressure. - Agents like **norepinephrine, phenylephrine, and dopamine** are commonly used in critical care settings. *Acute decompensated heart failure* - Sympathomimetics with **beta-1 adrenergic agonist** effects (e.g., **dobutamine**) can improve cardiac contractility and output in acute decompensated heart failure. - These agents help to **increase myocardial performance** in situations where the heart is failing to pump adequately. - They provide temporary hemodynamic support in acute settings. *Nasal congestion* - **Alpha-1 adrenergic agonists** (e.g., **phenylephrine, pseudoephedrine**) are widely used as nasal decongestants. - They cause **vasoconstriction of nasal blood vessels**, reducing mucosal edema and improving airflow. - Available as both topical nasal sprays and oral formulations for symptomatic relief of nasal congestion.

Q: Metyrosine is used in the treatment of?

Pheochromocytoma. ***Pheochromocytoma*** - **Metyrosine** inhibits **tyrosine hydroxylase**, the rate-limiting enzyme in **catecholamine synthesis**, thus reducing the production of **epinephrine** and **norepinephrine**. - Its primary use is in the preoperative management of **pheochromocytoma** to prevent **hypertensive crises** during surgery, and in patients with inoperable or metastatic disease to control symptoms. *Acromegaly* - **Acromegaly** is characterized by excessive **growth hormone** production. - Treatment typically involves **somatostatin analogs**, **GH receptor antagonists**, or surgery, not metyrosine. *Cushing syndrome* - **Cushing syndrome** results from prolonged exposure to **high cortisol levels**. - Management focuses on reducing **cortisol** production or surgical removal of the underlying cause, not primarily involving metyrosine. *Addison's disease* - **Addison's disease** is caused by **adrenal insufficiency** leading to deficient **cortisol** and **aldosterone**. - Treatment involves **hormone replacement therapy** with glucocorticoids and mineralocorticoids.

Q: Which of the following is the longest acting ocular beta blocker?

Levobunolol. ***Levobunolol*** - Levobunolol is the **longest-acting ocular beta-blocker**, with a duration of action of approximately **24 hours**, allowing for **once-daily dosing** in many patients. - It is a **non-selective beta-blocker** (blocks both beta-1 and beta-2 receptors) that effectively reduces intraocular pressure in glaucoma management. - Its extended duration makes it particularly convenient for patient compliance compared to other ocular beta-blockers. *Betaxolol* - Betaxolol is a **beta-1 selective blocker** with a duration of action of approximately **12 hours**, typically requiring **twice-daily dosing**. - Its selectivity may offer a better systemic safety profile regarding respiratory side effects compared to non-selective agents. - While effective, it does not have the longest duration of action among ocular beta-blockers. *Carteolol* - Carteolol is a **non-selective beta-blocker** with **intrinsic sympathomimetic activity (ISA)**. - It has a duration of action of approximately **12 hours** and usually requires **twice-daily administration**. - The ISA property may theoretically reduce some systemic side effects but does not extend its duration of action. *Timolol* - Timolol is a **non-selective beta-blocker** widely used in ophthalmology with a duration of action of approximately **12 hours**. - It typically requires **twice-daily dosing** and is highly effective for reducing intraocular pressure. - Its non-selective nature can lead to systemic side effects like **bronchospasm** in susceptible individuals.

Q: What distinguishes betaxolol from timolol in terms of its pharmacological properties?

Is a selective β1 blocker. ***Is a selective β1 blocker*** - **Betaxolol** is a **cardioselective β1-adrenergic antagonist**, meaning it primarily blocks β1 receptors in the heart and **juxtaglomerular apparatus**. - **Timolol**, in contrast, is a **non-selective β-blocker**, affecting both β1 and β2 receptors, which can lead to more systemic side effects. *Has superior efficacy in treating glaucoma* - Both betaxolol and timolol are effective in **reducing intraocular pressure (IOP)** by decreasing aqueous humor production, with **timolol generally showing equivalent or slightly greater efficacy**. - **Timolol's non-selective action** may sometimes lead to a marginal advantage in IOP reduction, though **betaxolol is preferred** in some patients due to its selectivity. *Causes fewer ocular side effects than timolol* - While betaxolol is generally associated with **fewer systemic side effects** due to its cardioselectivity, it can actually cause **more ocular stinging and irritation** compared to timolol. - Some studies suggest a comparable incidence of other ocular side effects like **dry eye or blurred vision** between the two drugs. *Has a shorter duration of action than timolol* - Both betaxolol and timolol are applied **topically once or twice daily** to manage glaucoma, indicating a **similar long duration of action** suitable for sustained IOP control. - There is no clinical evidence to suggest that betaxolol has a significantly shorter duration of action that would warrant more frequent dosing compared to timolol.

Q: Which of the following drugs possesses the maximum action on nicotinic receptors?

Carbachol. ***Carbachol*** - **Carbachol** is a stable choline ester with prominent **nicotinic agonist activity**, making it the cholinergic agent with the greatest action on nicotinic receptors among the options listed. - Its **dual muscarinic and nicotinic effects** are due to its chemical structure, making it less selective than some other cholinergic agents. *Bethanechol* - **Bethanechol** is a choline ester that primarily acts on **muscarinic receptors** and has very little to no nicotinic activity. - It is used clinically for its muscarinic effects, such as increasing **bladder motility** or treating **gastric atony**. *Pilocarpine* - **Pilocarpine** is an alkaloid with strong, selective **muscarinic agonist activity**, making it particularly useful for conditions like **glaucoma** (by increasing aqueous humor outflow) and **xerostomia**. - It exhibits negligible activity at **nicotinic receptors**. *Methacholine* - **Methacholine** is a choline ester that primarily stimulates **muscarinic receptors**, though it has more nicotinic action than bethanechol. - It is known for its use in **bronchial challenge tests** to diagnose **asthma** due to its role in causing bronchoconstriction via muscarinic stimulation.

Q: Which short-acting anticholinesterase drug is primarily used for the diagnosis of myasthenia gravis?

Edrophonium. ***Edrophonium*** - This **short-acting anticholinesterase** reversibly inhibits acetylcholinesterase, leading to a temporary increase in acetylcholine at the neuromuscular junction. - The **Tensilon test** uses edrophonium to rapidly assess for improved muscle strength in patients suspected of having myasthenia gravis. *Demecarium* - This is a **long-acting cholinesterase inhibitor** and is not typically used for the fast diagnostic test of myasthenia gravis due to its extended duration of action. - It was historically used in the treatment of glaucoma, not for acute diagnostic purposes in neuromuscular disorders. *Dyflos* - Also known as **diisopropyl fluorophosphate (DFP)**, Dyflos is an **irreversible organophosphorus cholinesterase inhibitor**. - Its long-lasting and toxic effects make it unsuitable and dangerous for diagnostic testing of myasthenia gravis. *Echothiophate* - This is another **long-acting, irreversible cholinesterase inhibitor** primarily used in the treatment of glaucoma. - Its irreversible nature and prolonged effects are not suitable for the quick, reversible diagnostic test needed for myasthenia gravis.

Q: Which of the following statements about d-tubocurarine is true?

Is a non-depolarizing neuromuscular blocking agent.. ***Is a non-depolarizing neuromuscular blocking agent*** - D-tubocurarine is a **classic non-depolarizing neuromuscular blocker (NDNMB)**, acting as a competitive antagonist at nicotinic receptors - This is the **fundamental classification** that defines its mechanism and distinguishes it from depolarizing agents like succinylcholine - Non-depolarizing agents can be reversed with anticholinesterases (neostigmine, pyridostigmine) *Causes histamine release leading to hypotension* - While this statement is **medically accurate**, d-tubocurarine does cause significant histamine release - This side effect leads to hypotension, bronchospasm, and tachycardia - However, this is a **side effect** rather than the primary defining characteristic of the drug *Blocks nicotinic receptors at the neuromuscular junction* - This statement is also **factually correct** - d-tubocurarine blocks nicotinic ACh receptors at NMJ - This is the **mechanism of action** of all non-depolarizing blockers - However, the classification as "non-depolarizing" is the broader, more fundamental concept tested *Has intermediate duration of action (30-60 minutes)* - This is **INCORRECT** - d-tubocurarine is classified as a **long-acting** neuromuscular blocker - Duration of action: **90-120+ minutes**, not intermediate - Intermediate-acting agents include atracurium, vecuronium, and rocuronium (30-60 min)

Question 1

Which of the following drugs is not used for the treatment of overactive bladder?

Accepted Answer

Duloxetine

Answer

Oxybutynin

Answer

Flavoxate

Answer

Darifenacin

Question 2

The drug used in an ameliorative test for myasthenia gravis is

Accepted Answer

Edrophonium

Answer

Physostigmine

Answer

Tacrine

Answer

Pyridostigmine

Question 3

Which of the following is not a carbamate?

Accepted Answer

Edrophonium

Answer

Physostigmine

Answer

Neostigmine

Answer

Pyridostigmine

Question 4

Sympathomimetic drugs are useful in the therapy of all of the following conditions except:

Accepted Answer

Hypertension

Answer

Hypotension

Answer

Acute decompensated heart failure

Answer

Nasal congestion

Question 5

Metyrosine is used in the treatment of?

Accepted Answer

Pheochromocytoma

Answer

Cushing syndrome

Answer

Addison's disease

Answer

Acromegaly

Question 6

Which of the following is the longest acting ocular beta blocker?

Accepted Answer

Levobunolol

Answer

Carteolol

Answer

Betaxolol

Answer

Timolol

Question 7

What distinguishes betaxolol from timolol in terms of its pharmacological properties?

Accepted Answer

Is a selective β1 blocker

Answer

Has superior efficacy in treating glaucoma

Answer

Causes fewer ocular side effects than timolol

Answer

Has a shorter duration of action than timolol

Question 8

Which of the following drugs possesses the maximum action on nicotinic receptors?

Accepted Answer

Carbachol

Answer

Bethanechol

Answer

Pilocarpine

Answer

Methacholine

Question 9

Which short-acting anticholinesterase drug is primarily used for the diagnosis of myasthenia gravis?

Accepted Answer

Edrophonium

Answer

Demecarium

Answer

Dyflos

Answer

Echothiophate

Question 10

Which of the following statements about d-tubocurarine is true?

Accepted Answer

Is a non-depolarizing neuromuscular blocking agent.

Answer

Causes histamine release leading to hypotension.

Answer

Blocks nicotinic receptors at the neuromuscular junction.

Answer

Has intermediate duration of action (30-60 minutes).

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?